You are herePharma News

Pharma News


Jubilant Life net profit lowered by 56.8% in Q4, dividend at 300%

Jubilant Life Sciences has suffered drop during the fourth quarter ended March 2015 due to lower sales and its consolidated net profit declined sharply by 56.8 per cent to Rs.42.73 crore from Rs.98.81 crore in the corresponding period of last year. Its consolidated net sales also declined by 1.9 per cent to Rs.1,523 crore from Rs.1,552 crore. EBIDTA improved marginally to Rs.253.27 crore from Rs.250.86 crore. EPS declined to Rs.2.68 from Rs.6.20 in the last period. The company management recommended equity dividend of 300 % for the year 2014-15.


India will share its part in first clinical study using stem cells to cure spinal cord injury

India will bea part of a first-of-its-kind clinical trial for treating spinal cord injury in humans through stem-cells involving 18 patients. The clinical trial is a part of a collaborative study conducted in China, Norway and America involving 240 patients. The pre-clinical trial of this project already completed in the US and also the first phase clinical trials in China involving 120 patients.


India and Mongolia comes closer for Traditional Systems of Medicine and Homoeopathy

The Union Cabinet chaired by the Prime Minister, Shri Narendra Modi, today gave its approval for signing of a Memorandum of Understanding (MoU) for cooperation in the field of Traditional Systems of Medicine and Homoeopathy between India and Mongolia.


US FDA granted Nevro's Senza spinal cord stimulation system

Nevro Corp., a medical device company focused on developing solutions in the neuromodulation spacea, has received approval from the United States Food and Drug Administration (FDA) for its Senza spinal cord stimulation (SCS) system. This is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.


Neusoft Medical Systems launch NeuViz 128 CT for global markets

Neusoft Medical Systems Co., Ltd. manufactures medical equipment, and provides medical IT solutions and healthcare services, introduced  NeuViz 128 CT for the global markets. The products are being exported to South Asia, North Africa and other international markets. It is leading-edge technologies and innovations to create super-fine and low dose images.


Stempeutics gets patent in China for Stempeucel

Stempeutics Research, a part of the Manipal Education and Medical Group (MEMG), has received process patent from the State Intellectual Property Office of China (SIPO) for its novel stem-cell based drug Stempeucel for the treatment of Critical Limb Ischemia (CLI), a progressive form of peripheral arterial disease.


Ajanta Pharma net surges by 20% in Q4, share at 300% for 2014-15

Ajanta Pharma posted satisfactory financial performance for the fourth quarter ended March 2015 and its standalone net profit increased by 20.3 per cent to Rs. 84.31 crore from Rs. 70.09 crore in the corresponding period of last year. EBIDTA increased by 22 per cent to Rs. 140.72 crore from Rs. 115.36 crore. Its net sales rise up by 19.7 per cent to Rs. 360.36 crore from Rs. 301.14 crore. Export is 67 per cent of the revenue for the quarter. R&D expenditure increased to Rs. 24 crore from Rs. 11 crore in the similar period of last year. The board of directors has approved equity share of 300 per cent for the year 2014-15.


GSK net earnings to £8,038 mn in Q1 boosts by other operating income

GlaxoSmithKline (GSK), has posted net profit of  £8,038 million during the first quarter ended March 2015 as against £719 million in the corresponding period of last year, mainly due to other operating income of £8,712 million. Its sales remained almost stagnant at £5,622 million as compared to £5,613 million. Its R&D expenditure increased to £867 million from £859 million.


Mylan launch generic Seasonale tablets in US market

Mylan NV, a global pharmaceutical company, launched levonorgestrel and ethinyl estradiol tablets USP, 0.15 mg/0.03 mg, generic version of Teva's Seasonale tablets, in the US.


Torrent Pharma gain entire stake in Zyg Pharma

Torrent Pharmaceuticals earn 100 percent equity stake in Zyg Pharma Pvt Ltd, a company engaged in manufacturing various dermatological formulations like creams, ointments, gels, lotions, solutions, for undisclosed price.